Published in Trends Pharmacol Sci on July 31, 2006
Analgesia mediated by soluble epoxide hydrolase inhibitors is dependent on cAMP. Proc Natl Acad Sci U S A (2011) 1.45
Epoxygenated fatty acids and soluble epoxide hydrolase inhibition: novel mediators of pain reduction. J Agric Food Chem (2010) 0.94
The case for the development of novel analgesic agents targeting both fatty acid amide hydrolase and either cyclooxygenase or TRPV1. Br J Pharmacol (2009) 0.94
Sensitization of meningeal nociceptors: inhibition by naproxen. Eur J Neurosci (2008) 0.93
Rationally designed multitarget agents against inflammation and pain. Curr Med Chem (2013) 0.91
Soluble epoxide hydrolase limits mechanical hyperalgesia during inflammation. Mol Pain (2011) 0.88
Combined analgesics in (headache) pain therapy: shotgun approach or precise multi-target therapeutics? BMC Neurol (2011) 0.85
Acanthopanax koreanum fruit waste inhibits lipopolysaccharide-induced production of nitric oxide and prostaglandin E2 in RAW 264.7 macrophages. J Biomed Biotechnol (2010) 0.84
Localization of COX-1 and COX-2 in the intracranial dura mater of the rat. Neurosci Lett (2009) 0.83
Novel strategies for the treatment of inflammatory hyperalgesia. Eur J Clin Pharmacol (2010) 0.81
[From willow bark to the coxibs. Development of antiphlogistic analgesics]. Schmerz (2007) 0.81
Heterogeneous presynaptic distribution of monoacylglycerol lipase, a multipotent regulator of nociceptive circuits in the mouse spinal cord. Eur J Neurosci (2014) 0.80
Inhibition of Pro-inflammatory Mediators and Cytokines by Chlorella Vulgaris Extracts. Pharmacognosy Res (2016) 0.80
Anti-Inflammatory Effects of Novel Standardized Solid Lipid Curcumin Formulations. J Med Food (2014) 0.79
Anti-inflammatory potential of ellagic acid, gallic acid and punicalagin A&B isolated from Punica granatum. BMC Complement Altern Med (2017) 0.79
Analgesic targets: today and tomorrow. Inflammopharmacology (2009) 0.79
Toll-like receptor 6 mediated inflammatory and functional responses of zinc oxide nanoparticles primed macrophages. Immunology (2014) 0.77
Expression of mPGES-1 and IP mRNA is reduced by LLLT in both subplantar and brain tissues in the model of peripheral inflammation induced by carrageenan. Lasers Med Sci (2014) 0.76
Enhanced anti-inflammatory potential of cinnamate-zinc layered hydroxide in lipopolysaccharide-stimulated RAW 264.7 macrophages. Drug Des Devel Ther (2015) 0.75
Engineered heart tissue grafts improve systolic and diastolic function in infarcted rat hearts. Nat Med (2006) 4.74
A genome-wide Drosophila screen for heat nociception identifies α2δ3 as an evolutionarily conserved pain gene. Cell (2010) 2.37
Reversal of pathological pain through specific spinal GABAA receptor subtypes. Nature (2008) 2.30
Acetaminophen (paracetamol) is a selective cyclooxygenase-2 inhibitor in man. FASEB J (2007) 2.00
Blockade of TNF-α rapidly inhibits pain responses in the central nervous system. Proc Natl Acad Sci U S A (2011) 1.95
The impact of unlicensed and off-label drug use on adverse drug reactions in paediatric patients. Drug Saf (2004) 1.57
Cyclooxygenase-2--10 years later. J Pharmacol Exp Ther (2002) 1.44
Engineering of vascularized transplantable bone tissues: induction of axial vascularization in an osteoconductive matrix using an arteriovenous loop. Tissue Eng (2006) 1.40
In vivo magnetic resonance imaging of dendritic cell migration into the draining lymph nodes of mice. Eur J Immunol (2006) 1.31
Spinal inflammatory hyperalgesia is mediated by prostaglandin E receptors of the EP2 subtype. J Clin Invest (2005) 1.30
Simultaneous determination of aceclofenac and three of its metabolites in human plasma by high-performance liquid chromatography. Biomed Chromatogr (2003) 1.29
Survey of adverse drug reactions on a pediatric ward: a strategy for early and detailed detection. Pediatrics (2002) 1.23
Role of p-glycoprotein inhibition for drug interactions: evidence from in vitro and pharmacoepidemiological studies. Clin Pharmacokinet (2007) 1.14
Identification of adverse drug reactions in geriatric inpatients using a computerised drug database. Drugs Aging (2003) 1.12
A role for endocannabinoids in indomethacin-induced spinal antinociception. Eur J Pharmacol (2002) 1.10
Polymorphisms of TLR4: rapid genotyping and reduced response to lipopolysaccharide of TLR4 mutant alleles. Clin Chem (2002) 1.10
Caffeine accelerates absorption and enhances the analgesic effect of acetaminophen. J Clin Pharmacol (2007) 1.07
Lack of awareness of community-acquired adverse drug reactions upon hospital admission : dimensions and consequences of a dilemma. Drug Saf (2003) 1.03
Gene expression changes in blood after phlebotomy: implications for gene expression profiling. Blood (2002) 1.02
Combining functional magnetic resonance imaging with mouse genomics: new options in pain research. Neuroreport (2010) 0.96
Drug utilisation on a preterm and neonatal intensive care unit in Germany: a prospective, cohort-based analysis. Eur J Clin Pharmacol (2009) 0.96
Imaging of hyperalgesia in rats by functional MRI. Eur J Pain (2006) 0.95
Dipyrone elicits substantial inhibition of peripheral cyclooxygenases in humans: new insights into the pharmacology of an old analgesic. FASEB J (2007) 0.94
Stabilization of gene expression profiles in blood after phlebotomy. Clin Chem (2002) 0.94
15-Deoxy-Delta(12,14)-prostaglandin J2 inhibits the expression of proinflammatory genes in human blood monocytes via a PPAR-gamma-independent mechanism. Biochem Biophys Res Commun (2003) 0.94
Are computerised monitoring systems of value to improve pharmacovigilance in paediatric patients? Eur J Clin Pharmacol (2006) 0.94
Paracetamol, ibuprofen, or a combination of both drugs against knee pain: an excellent new randomised clinical trial answers old questions and suggests new therapeutic recommendations. Ann Rheum Dis (2011) 0.93
Evaluation of NT-proBNP and high sensitivity C-reactive protein for predicting cardiovascular risk in patients with arthritis taking longterm nonsteroidal antiinflammatory drugs. J Rheumatol (2011) 0.93
Regulation of IL-13 synthesis in human lymphocytes: implications for asthma therapy. Br J Pharmacol (2002) 0.92
Latanoprost induces matrix metalloproteinase-1 expression in human nonpigmented ciliary epithelial cells through a cyclooxygenase-2-dependent mechanism. FASEB J (2005) 0.91
Celecoxib inhibits metabolism of cytochrome P450 2D6 substrate metoprolol in humans. Clin Pharmacol Ther (2003) 0.88
Simultaneous determination of leflunomide and its active metabolite, A77 1726, in human plasma by high-performance liquid chromatography. Biomed Chromatogr (2003) 0.88
R(+)-methanandamide and other cannabinoids induce the expression of cyclooxygenase-2 and matrix metalloproteinases in human nonpigmented ciliary epithelial cells. J Pharmacol Exp Ther (2005) 0.88
Drug insight: cyclo-oxygenase-2 inhibitors--a critical appraisal. Nat Clin Pract Rheumatol (2007) 0.87
Kinetics and functional characterization of the glycine receptor alpha2 and alpha3 subunit. Neurosci Lett (2007) 0.87
Up-regulation of cyclooxygenase-2 expression is involved in R(+)-methanandamide-induced apoptotic death of human neuroglioma cells. Mol Pharmacol (2004) 0.87
Intrinsic versus extrinsic vascularization in tissue engineering. Adv Exp Med Biol (2006) 0.87
Normal sensitivity to acute pain, but increased inflammatory hyperalgesia in mice lacking the nociceptin precursor polypeptide or the nociceptin receptor. Eur J Neurosci (2003) 0.87
More pronounced inhibition of cyclooxygenase 2, increase in blood pressure, and reduction of heart rate by treatment with diclofenac compared with celecoxib and rofecoxib. Arthritis Rheum (2006) 0.87
Paracetamol and cyclooxygenase inhibition: is there a cause for concern? Ann Rheum Dis (2011) 0.86
Prostaglandin E2 induces cyclooxygenase-2 expression in human non-pigmented ciliary epithelial cells through activation of p38 and p42/44 mitogen-activated protein kinases. Biochem Biophys Res Commun (2005) 0.86
Pain and osteoarthritis: new drugs and mechanisms. Curr Opin Rheumatol (2004) 0.86
Inhibitors of mitogen-activated protein kinases differentially regulate costimulated T cell cytokine production and mouse airway eosinophilia. Respir Res (2005) 0.86
Lipopolysaccharide-induced lung inflammation is inhibited by neutralization of GM-CSF. Eur J Pharmacol (2006) 0.85
E-pharmacovigilance: development and implementation of a computable knowledge base to identify adverse drug reactions. Br J Clin Pharmacol (2013) 0.85
Consumption of analgesics before a marathon and the incidence of cardiovascular, gastrointestinal and renal problems: a cohort study. BMJ Open (2013) 0.85
Aceclofenac spares cyclooxygenase 1 as a result of limited but sustained biotransformation to diclofenac. Clin Pharmacol Ther (2003) 0.84
R(+)-methanandamide-induced cyclooxygenase-2 expression in H4 human neuroglioma cells: possible involvement of membrane lipid rafts. Biochem Biophys Res Commun (2004) 0.84
Synergistic effects of the anti-cholinergic R,R-glycopyrrolate with anti-inflammatory drugs. Biochem Pharmacol (2006) 0.83
Can drug removals involving cyclooxygenase-2 inhibitors be avoided? A plea for human pharmacology. Trends Pharmacol Sci (2008) 0.83
Investigation of the pharmacokinetics of celecoxib by liquid chromatography-mass spectrometry. Biomed Chromatogr (2002) 0.83
Determination of the endocannabinoid anandamide in human plasma by high-performance liquid chromatography. Biomed Chromatogr (2006) 0.82
Influence of cyclooxygenase inhibitors on the function of the prostaglandin transporter organic anion-transporting polypeptide 2A1 expressed in human gastroduodenal mucosa. J Pharmacol Exp Ther (2009) 0.82
Absorption and distribution of etoricoxib in plasma, CSF, and wound tissue in patients following hip surgery--a pilot study. Naunyn Schmiedebergs Arch Pharmacol (2010) 0.81
Hypoxia induced chemokine expression in nasal epithelial cells: development of an in vitro model for chronic rhinosinusitis. ALTEX (2006) 0.81
Bioavailability of diclofenac potassium at low doses. Br J Clin Pharmacol (2005) 0.81
N-terminal prohormone brain natriuretic peptide: a biomarker for detecting cardiovascular risks in patients with rheumatoid arthritis or osteoarthritis? Ann Rheum Dis (2007) 0.81
Ceramide is involved in r(+)-methanandamide-induced cyclooxygenase-2 expression in human neuroglioma cells. Mol Pharmacol (2003) 0.80
Effect of amiodarone on the plasma levels of metoprolol. Am J Cardiol (2004) 0.80
Cytochrome p450 polymorphisms in geriatric patients: impact on adverse drug reactions--a pilot study. Drugs Aging (2005) 0.79
Herbal remedies for asthma treatment: between myth and reality. Drugs Today (Barc) (2002) 0.79
Cardiovascular effects of selective COX-2 inhibition: is there a class effect? The International COX-2 Study Group. J Rheumatol (2006) 0.79
Lateralization of responses to vibrissal stimulation: connectivity and information integration in the rat sensory-motor cortex assessed with fMRI. Neuroimage (2012) 0.79
Cytokine profiles of cord and adult blood leukocytes: differences in expression are due to differences in expression and activation of transcription factors. BMC Immunol (2007) 0.79
New problems arising from old drugs: second-generation effects of acetaminophen. Expert Rev Clin Pharmacol (2014) 0.79
Advances in NSAID development: evolution of diclofenac products using pharmaceutical technology. Drugs (2015) 0.77
Osteoporosis in a young woman after 6 years of levonorgestrel administration from intrauterine devices? BMJ Case Rep (2009) 0.77
Refinement and reduction in animal experimentation: options for new imaging techniques. ALTEX (2008) 0.76
Simultaneous determination of oxycodone and its major metabolite, noroxycodone, in human plasma by high-performance liquid chromatography. Biomed Chromatogr (2005) 0.76
Platelet inhibitory effects of OTC doses of naproxen sodium compared with prescription dose naproxen sodium and low-dose aspirin. Curr Med Res Opin (2009) 0.76
Anti-inflammatory effects of a cyclosporine receptor-binding compound, D-43787. J Pharmacol Exp Ther (2002) 0.76
A role for cyclooxygenase-1 in neuropathic pain? Anesthesiology (2003) 0.75
Effect of maximum OTC doses of naproxen sodium or acetaminophen on low-dose aspirin inhibition of serum thromboxane B2. Curr Med Res Opin (2010) 0.75
A validated high-performance liquid chromatographic assay for determination of lumiracoxib in human plasma. Biomed Chromatogr (2006) 0.75
Induction of COX-2 expression by the endocannabinoid derivative R(+)-methanandamide. Adv Exp Med Biol (2003) 0.75
[Acute backache guideline clearing process. Methodology and results of formal evaluation]. Z Orthop Ihre Grenzgeb (2003) 0.75
Effect of selective cyclooxygenase-2 inhibitors on heart rate in healthy young men. Am J Cardiol (2005) 0.75
R(+)-methanandamide elicits a cyclooxygenase-2-dependent mitochondrial apoptosis signaling pathway in human neuroglioma cells. Pharm Res (2006) 0.75
Unconventional therapies in asthma. Drugs Today (Barc) (2001) 0.75
COX-2 selective inhibitors--they are still the best treatment for many patients! Swiss Med Wkly (2005) 0.75
[Lumiracoxib taken off the market in Australia. What does that mean for our patients? (interview by Dr. Judith Neumaier)]. MMW Fortschr Med (2007) 0.75
A liquid chromatography-mass spectrometry method for the quantification of both etoricoxib and valdecoxib in human plasma. Biomed Chromatogr (2005) 0.75
[Randomized double blind study on traditional Chinese medicine. evidence remains questionable]. MMW Fortschr Med (2008) 0.75
RNA-based drug screening using automated RNA purification and real-time RT-PCR1. J Biomol Screen (2004) 0.75